Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology. 2002, 123 (6): 2108-2131. 10.1053/gast.2002.37095.
Article
PubMed
Google Scholar
Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ: Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002, 20 (7): 455-462. 10.2165/00019053-200220070-00003.
Article
PubMed
Google Scholar
Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W: Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010, 55 (3): 716-723. 10.1007/s10620-009-0765-9.
Article
CAS
PubMed
Google Scholar
Spiegel BM, Chey WD, Chang L: Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. Am J Gastroenterol. 2008, 103 (12): 2972-2976. 10.1111/j.1572-0241.2008.01992.x.
Article
PubMed
PubMed Central
Google Scholar
Stichting Farmaceutische Kerngetallen (SKF): Facts and figures 2009. 2010, Available from: http://www.sfk.nl/pdf-documenten/data-en-feiten/data-en-feiten-2009, accessed 15 August,
Google Scholar
Forgacs I, Loganayagam A: Overprescribing proton pump inhibitors. BMJ. 2008, 336 (7634): 2-3. 10.1136/bmj.39406.449456.BE.
Article
PubMed
PubMed Central
Google Scholar
van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD: Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009, 29 (5): 571-579. 10.1111/j.1365-2036.2008.03900.x.
Article
CAS
PubMed
Google Scholar
Goettsch WG, van den Boom G, Breekveldt-Postma NS, Smout AJ, Herings RM: Treatment patterns and health care costs of mebeverine-treated IBS patients: a case–control study. Pharmacoepidemiol Drug Saf. 2004, 13 (11): 803-810. 10.1002/pds.997.
Article
PubMed
Google Scholar
Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA: Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study. Aliment Pharmacol Ther. 2010, 32 (9): 1124-1128. 10.1111/j.1365-2036.2010.04453.x.
Article
CAS
PubMed
Google Scholar
Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn WJ: Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007, 13 (2): 175-181. 10.1002/ibd.20059.
Article
PubMed
Google Scholar
Burgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002, 123 (2): 433-443. 10.1053/gast.2002.34784.
Article
PubMed
Google Scholar
Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G, et al: Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008, 28 (11–12): 1317-1325.
Article
CAS
PubMed
Google Scholar
Lombardo L, Foti M, Ruggia O, Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010, 8 (6): 504-508. 10.1016/j.cgh.2009.12.022.
Article
PubMed
Google Scholar
Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC: Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011, 141 (5): 769-776. 10.3945/jn.110.135657.
Article
CAS
PubMed
Google Scholar
Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD: Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003, 98 (11): 2454-2459. 10.1111/j.1572-0241.2003.07699.x.
Article
PubMed
Google Scholar
Ford AC, Marwaha A, Lim A, Moayyedi P: Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010, 8 (5): 401-409. 10.1016/j.cgh.2009.07.020.
Article
PubMed
Google Scholar
Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ: Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol. 2000, 95 (1): 157-165. 10.1111/j.1572-0241.2000.01678.x.
Article
PubMed
Google Scholar
Talley NJ, Zinsmeister AR, Melton LJ: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995, 142 (1): 76-83.
CAS
PubMed
Google Scholar
Bjarnason I, MacPherson A, Hollander D: Intestinal permeability: an overview. Gastroenterology. 1995, 108 (5): 1566-1581. 10.1016/0016-5085(95)90708-4.
Article
CAS
PubMed
Google Scholar
Kalantar JS, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ: Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. Aliment Pharmacol Ther. 2003, 17 (11): 1389-1397. 10.1046/j.1365-2036.2003.01591.x.
Article
CAS
PubMed
Google Scholar
Bjarnason I, Hayllar J, MacPherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993, 104 (6): 1832-1847.
Article
CAS
PubMed
Google Scholar
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005, 128 (5): 1172-1178. 10.1053/j.gastro.2005.03.020.
Article
PubMed
Google Scholar
Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, et al: Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest. 2010, 40 (6): 504-510. 10.1111/j.1365-2362.2010.02290.x.
Article
CAS
PubMed
Google Scholar
Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, et al: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011, 141 (4): 1314-1322. 10.1053/j.gastro.2011.06.075. 1322 e1311-1315
Article
CAS
PubMed
Google Scholar
Lewis SJ, Franco S, Young G, O'Keefe SJ: Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996, 10 (4): 557-561. 10.1046/j.1365-2036.1996.d01-506.x.
Article
CAS
PubMed
Google Scholar
Williams C, McColl KE: Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006, 23 (1): 3-10. 10.1111/j.1365-2036.2006.02707.x.
Article
CAS
PubMed
Google Scholar
Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, et al: Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996, 39 (1): 54-59. 10.1136/gut.39.1.54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, Blum A, Bille J, Gonvers JJ, Gyr K: Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994, 35 (1): 23-26. 10.1136/gut.35.1.23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Spiegel BM: Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011, 9 (6): 461-469. 10.1016/j.cgh.2011.02.030. quiz e459
Article
PubMed
Google Scholar
Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA: Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011, 33 (9): 1059-1067. 10.1111/j.1365-2036.2011.04625.x.
Article
CAS
PubMed
Google Scholar
Keszthelyi D, Masclee AA: Effects of proton pump inhibitor therapy in the distal gut: putting the pieces together. Dig Dis Sci. 10.1007/s10620-012-2339-5. Epub 17 Aug 2012